| | Univariate | | | Multivariate | | |
---|
| | | | | R2 = 0.05 | | |
---|
| | β (95%CI) | t |
P
| β (95%CI) | t |
P
|
---|
Adrenaline | 100 pg/ml | 1.64 (0.58 to 2.71) | 3 |
0.003
| | | NS |
Noradrenaline | 100 pg/ml | 1.20 (0.57 to 1.84) | 4 |
<0.001
| 1.12 (0.46 to 1.78) | 3 |
0.001
|
Male gender | yes | -24 (-41 to-8) | -3 |
0.004
| | | NS |
Diabetes | yes | 29 (4 to 54) | 2 |
0.024
| 31 (3 to 58) | 2 |
0.032
|
eGFR | ml/min | -0.41 (-0.72 to-0.10) | -3 |
0.009
| | | NS |
Peak TnI | µg/L | 0.04 (0 to 0.08) | 2 | 0.051 | | | NS |
Shock prior to pPCI | yes | 43 (17 to 69) | 3 |
0.002
| 35 (8 to 61) | 3 |
0.010
|
- Regression coefficients (β) with 95% confidence intervals (95%CI), t-and P-values and R2 displayed for the multivariate models. P-values are shown in bold for variables with P <0.05. Predicted change in syndecan-1 (pg/ml) associated with one unit increase in adrenaline, noradrenaline, eGFR and peak TnI, being male or having diabetes or shock prior to pPCI. eGFR, estimated glomerular filtration rate; pPCI, percutaneous primary coronary intervention; STEMI, ST elevation myocardial infarction; TnI, troponin I.